1. Explain how predictive hemostasis biomarkers (including APC resistance–based global tests) can be used to quantify the prothrombotic impact of COCs and connect mechanistic changes to VTE risk.
  2. Integrate findings across study types—clinical trials with surrogate endpoints, cohort studies/registries, meta-analyses, and real-world evidence—to build a coherent, regulator-relevant benefit–risk narrative for COC-associated VTE
  3. Interpret pharmacovigilance signal-detection outputs (e.g., disproportionality metrics) appropriately, including key limitations, and triangulate them with biomarker and epidemiologic evidence.
Session date: 
04/14/2026 - 8:00am to 9:00am CDT
Location: 
Endeavor Health, Glenbrook Hospital
2100 Pfingsten Rd
Cardiovascular Institute Building, 2nd Floor, Conference Room #2843 (Take Elevator I)
Glenview, IL 60026
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or create an account to proceed.
Speaker Name: 
Jonathan Douxfils, PhD